Spinal Muscular Atrophy (SMA) is the most common genetic cause of infant mortality. SMA is caused by loss of functional Survival Motor Neuron 1 (SMN1), resulting in death of spinal motor neurons. Current therapeutic research focuses upon modulating the expression of a partially functioning copy gene, SMN2, which is retained in SMA patients. However, a treatment strategy that improves the SMA phenotype by slowing or reversing the skeletal muscle atrophy may also be beneficial. Myostatin, a member of the TGF-β super-family, is a potent negative regulator of skeletal muscle mass. Follistatin is a natural antagonist of myostatin and over-expression of follistatin in mouse muscle leads to profound increases in skeletal muscle mass. To determine whether enhanced muscle mass impacts SMA, we administered recombinant follistatin to a SMA mouse model. Treated animals exhibited increased mass in several muscle groups, elevation in the number and cross-sectional area of ventral horn cells, gross motor function improvement, and mean lifespan extension by 30%, by preventing some of the early deaths, as compared to control animals. SMN protein levels in spinal cord and muscle were unchanged in follistatin-treated SMA mice, suggesting that follistatin exerts its effect in an SMN-independent manner. Reversing muscle atrophy associated with SMA may represent an unexploited therapeutic target for the treatment of SMA.
INTRODUCTION
Delivery of therapeutic agents to the central nervous system for neurodegenerative diseases faces significant obstacles. Therefore, additional targets have been sought that are more accessible, such as skeletal muscle. Enhancing muscle mass has received attention as a potential therapeutic target for the treatment of neuromuscular disorders and muscle wasting diseases (1, 2) . This proposed therapy does not directly target the disease-causing gene, but rather targets pathways that positively affect muscle maintenance and growth. One potentially promising target is myostatin.
Myostatin is a member of the TGF-β family and is expressed almost exclusively in muscle (3) . It functions as potent negative regulator of muscle growth, and its inhibition or genetic ablation increases muscle mass and strength developmentally and in the adult (4, 5) . Specifically, myostatin knockout animals, in comparison to wild-type, display an increased number of fast type II fibers and a decreased number of slow type I fibers (6) . This change has been shown to be a result of altered development in these animals, implicating myostatin functionality in formation, proliferation or differentiation of developing muscle fibers (6) . The structure and function of myostatin is highly conserved across species, and loss of functional myostatin results in increased muscle mass also in dogs, cattle, and human (7) (8) (9) . Myostatin activity can be significantly reduced by neutralizing antibodies and several proteins that bind to myostatin and inhibit its activity, including follistatin, follistatin-related gene (FLRG) and growth and differentiation factorassociated serum protein-1 (GASP-1) (10) (11) (12) . This suggests that modulation of the myostatin signaling pathway could be exploited therapeutically. In support of this notion, the introduction of 4 myostatin antibody improved the pathophysiology of the mdx mouse (14, 15) . Viral delivery of the inhibitory myostatin propeptide was also efficient in muscular dystrophy due to calpain deficiency, but not α-sarcoglycan deficiency (16) . Schuelke et al. reported extensively developed musculature in the absence of adverse effects in a baby with an inactivating mutation in both myostatin alleles (9) . This suggests that myostatin blockade may become a therapeutically relevant approach to modulate muscle mass in humans. Further support comes from the recent completion of a phase I/II clinical trial of MYO-029, a neutralizing antibody, that showed adequate safety and limited efficacy (17) .
Follistatin is a cystine-rich glycoprotein that binds to and inhibits several TGF-β family members (18, 19) , including myostatin (5, 20, 21) . Similar to myostatin null mice, animals overexpressing follistatin also exhibit a nearly two-fold increase in muscle mass (5). Interestingly, follistatin over-expression in a myostatin-null background leads to an even greater increase in muscle mass, to nearly four-fold normal levels, indicating that follistatin increases muscle mass at least in part through myostatin-independent pathways (22) . Follistatin has been successfully employed to enhance muscle in mouse models of disease. Follistatin delivered by recombinant adeno-associated virus increases muscle mass in both wild type mice and mouse models of ALS and Duchenne muscular dystrophy (23, 24) . Importantly, not only did muscle proximal to the site of injection gain in mass, but muscles distant from the site of injection increased in weight as well (23, 24) .
SMA is a neurodegenerative disease and the leading genetic cause of infant death (25) .
With a carrier frequency of 1:40, and an incidence of 1:6,000 live births, SMA is the second most common autosomal recessive disorder. SMA presents in a broad clinical spectrum, but all cases result from the loss the Survival Motor Neuron 1 (SMN1) gene (26 (27) . The human genome, however, contains a second nearly identical gene called SMN2 (28) . In the absence of SMN1, the SMN2 locus cannot prevent disease development, as one of the nucleotide differences disrupts a critical pre-mRNA regulatory element within exon 7, resulting in the production of a truncated and unstable SMN protein (29) (30) (31) . However, SMN2 is clearly a potent disease modifier as increasing SMN2 gene copy numbers correlate with less severe forms of disease. This is possible since SMN2 does produce fully functional, full-length SMN protein, albeit at approximately 10% of the levels expressed by SMN1. (Fig. 1A) . This difference was even more pronounced at p10, when follistatin treatment resulted in significantly larger gastrocnemius and triceps muscles, approaching the weight of muscles from wildtype littermates (Fig. 1B) . As expected, as disease progression advanced and the animals approached end stage, muscle weights were similar between PBS-and follistatin-treated animals (Fig. 1C ). To account for potential variation in animal size, results are shown as muscle weights indexed to brain weights.
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RESULTS
The
Comparison of raw muscle weights gave virtually identical results (data not shown). To more closely analyze the muscle phenotype in treated SMA mice, muscle fiber size was examined at p6, p10, and p16 in the triceps brachii. Cross-sectional areas were not significantly different between vehicle-and follistatin-treated mice (Supplementary Material, S1). This result was 7 somewhat surprising since myostatin blockade has been shown to increase muscle fiber size (5).
However, transgenic overexpression of follistatin correlated to an approximate 1.6-fold increase in fiber area with a 327% increase in muscle weight (5) . In our treatment model, we observe a more modest increase in muscle weight between 20 and 25%, and it is therefore likely that a proportional increase in fiber area would be too small to detect reliably. These data demonstrate that neonatal follistatin administration confers a temporal gain of muscle mass in SMA mice during the course of this rapidly developing neurodegenerative disease.
To determine if follistatin treatment affects the severity of the SMA phenotype, we measured time-to-right (TTR) for PBS-or follistatin-treated SMA pups. TTR was previously
shown to be a sensitive measurement of gross motor function for these SMA animals (34, 35) . To determine TTR, animals were placed on their backs and the time required to turn upright was approximately 30% (Fig. 3A-C) . It is important to note that this change is seen not by altering the maximum lifespan, but rather by preventing the earlier deaths, thus an increase in the mean survival is observed. Additionally, the early deaths occurring in the vehicle-treated group were not observed in the 1 mg/kg q.a.d. treatment group. While the basis for the different outcomes of these dosing regimens is currently unknown, these findings demonstrate that even in a relatively severe model of disease, follistatin administration can significantly extend survival of SMA mice.
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Expression of follistatin in muscles of a different model of muscle wasting, the SOD-1 ALS model, was recently shown to increase muscle mass but did not affect survival (23) , suggesting that the effects of follistatin on survival may be disease-specific.
Since follistatin is a known inducer of muscle mass, we hypothesized that the lessening of disease severity was SMN-independent. Therefore, we examined SMN levels in tissues from follistatin-treated SMA animals. SMN levels were determined using p10 mice of the 0.75 mg/kg b.i.d. treatment group. This experimental group was selected based upon the phenotypic assessment demonstrating that timed-righting and muscle weight differences were most pronounced at this stage. Tissues from p10 animals were dissected and analyzed by Western blotting for SMN protein levels. As expected, in tissues from SMA mice, SMN levels were dramatically lower than those observed in wildtype tissues, since only low levels of full-length SMN are produced by the SMN2 transgene. Consistent with our hypothesis, follistatin treatment did not elevate SMN in spinal cord ( Fig. 4A and B) or triceps muscle ( Fig. 4C and D) , and protein levels were statistically equivalent to those of the vehicle group. Plastin-3 was recently identified as a potential SMA-modifying gene and its expression lessens the severity of disease (32) . To determine whether expression of this gene correlated with the lessening of the disease phenotype in follistatin-treated animals, plastin-3 levels were examined in the follistatin-and PBS-treated mice. Spinal cord protein extracts of p10 SMA pups were examined by Western blot, demonstrating that plastin-3 levels were similar in follistatin-treated, PBS-treated pups, and wildtype animals ( Fig. 4E and F ). These results demonstrate that the observed motor improvement was not correlated to changes in plastin-3 or full-length SMN levels.
Several models of disease suggest a potentially protective interplay between both sides of the neuromuscular junction. In an ALS model, insulin-like growth factor I expression in muscle results in increased motor neuron survival (36, 37) , whereas enhancing the functionality of the neuromuscular junction by maintaining the expression of postsynaptic proteins ameliorates the phenotype in a mouse model of muscular dystrophy (38) . Therefore, we speculated that enhanced muscle mass may lessen the severity of the SMA phenotype in part by preserving or maintaining neuronal circuitry. Spinal cord sections were analyzed to determine the number and size of ventral horn cell numbers in follistatin-, PBS-treated and wildtype animals ( Fig. 5A-C) . Analysis of ventral horn cells (VHCs) demonstrated that spinal cord sections from follistatin-treated animals contained approximately 180 VHCs as compared to 110 in vehicle controls (Fig. 5D ). While
VHCs in follistatin-treated sections were not as abundant as in wildtype animals, they were significantly greater in numbers compared to vehicle-treated counterparts (P < .02; Fig. 5D ).
Furthermore, the average cross-sectional area of the VHCs from follistatin-treated mice was larger than those of SMA mice treated with PBS and comparable to those of wildtype animals (Fig. 5E ).
These results suggest that follistatin treatment can delay the death of spinal motor neurons in a relatively severe mouse model of SMA and that induction of known and potential modifiers of disease, SMN2 and plastin-3, are not obligate components of this process. We provide evidence that enhanced muscle mass in SMA improves gross motor function, which is consistent with the cellular analysis of treated animals indicating a neural protective effect for VHCs. Taken together, our results demonstrate that follistatin treatment lessens the severity of the SMA phenotype and can increase mean survival in this relatively severe model of disease. The identification of a SMN-independent therapeutic target raises the possibility that combinatorial therapy aimed at increasing both muscle mass and SMN levels may prove beneficial.
DISCUSSION
The findings presented here demonstrate that administration of follistatin and the subsequent inhibition of the myostatin pathway is beneficial in a model of a neurodegenerative disorder, SMA. Life span and gross motor function was improved concomitant with an increase in muscle mass and the preservation of VHCs. While most work in the SMA field has focused upon targeting the SMN2 gene, these results suggest that skeletal muscle is a viable therapeutic target that may ameliorate the severity of the SMA phenotype. Consistent with this, follistatin-treated SMA mice performed better than their vehicle-treated SMA littermates in a series of timedrighting experiments designed to monitor gross motor function. This improvement was particularly pronounced between p6 and p10 in the 0.75 mg/kg b.i.d treatment group (Fig. 2 ).
Since muscle mass was increased during this period as well ( While it is clear that the presence of SMN2 provides an excellent target for therapeutic intervention, it was important to demonstrate in these studies that follistatin treatment did not alter the expression level of SMN protein (Fig. 4) . This finding was not surprising because follistatin is not known to modulate SMN levels. Therefore, our results indicate that the lessening of the SMA phenotype occurred in an SMN-independent fashion. Motor improvements and increased life span were also observed after treatment of SMA mice with TSA, a potent histone deacetylase inhibitor (34) . In this study, histological and molecular analyses demonstrated increased muscle fiber diameters and improved postnatal muscle development. In parallel, SMN2-derived transcripts and SMN protein levels were increased, suggesting that the beneficial effects of TSA were at least partly mediated by the transcriptional regulation of a key SMA modifier gene, SMN2 (34) . Using a different genetic model of disease, Grondard and colleagues demonstrated improved motor behavior and extended survival in response to exercise in a relatively severe mouse model of SMA (41) . In this study, increased levels of SMN protein were detected using immunohistochemistry of spinal cord sections. The increase in protein correlated with an increase in exon 7 inclusion in SMN2-derived transcripts (41) . Collectively, the authors demonstrated a connection between the induction of SMN2 expression and exercise, although a role for SMNindependent modes of action were not examined. Further analyses of trophic factor expression and recruitment of motor units may shed light on additional influences of exercise on the SMA phenotype in this model. Interestingly, exercise decreases levels of myostatin and increases levels of follistatin in humans and rodents (42) . It is therefore possible that follistatin administration elicits a subset of the more global exercise effects.
Although SMN is a ubiquitously expressed protein, its loss results in the selective death of spinal motor neurons. It is still somewhat controversial whether SMN deficiency in muscle contributes to the development of SMA, or if it is exclusively the reduction of SMN in the motor neurons that causes disease. Our report is not germane to that controversy because the beneficial effects of follistatin administration are independent of SMN protein levels. Recently, plastin-3 was identified as a potential novel modifier gene for SMA (32) . Plastin-3 was shown to promote axon outgrowth by increasing F-actin levels, thereby rescuing the axonal defects due to SMN knockdown in a zebrafish model without affecting SMN levels. This finding is the first to identify 14 an SMN-independent molecular target for the modification of the SMA phenotype. We found that follistatin treatment did not alter plastin-3 levels in the SMA mice (Figure 4 ), suggesting that inhibition of the myostatin pathway offers a tractable, SMN-independent target to modulate the SMA phenotype.
A possible mechanism underlying the phenotypic improvement of follistatin-treated SMA mice is suggested by the increased number and size of VHCs in the lumbar spinal cord ( Figure 5 ). We hypothesize that follistatin does not regulate VHC numbers directly, but rather indirectly via its muscle enhancing activity. This view is supported by the finding that an increase in muscle mass (e.g., by exercise) leads to changes in the gene expression profile of the spinal cord, including the upregulation of anti-apoptotic genes (43) . Similarly, the positive impact of exercise (41) It is tempting to speculate that improving muscle by various means leads to increased survival of VHCs, thereby lessening the severity of SMA. The findings presented in this report do not specifically examine the role of the muscle versus neuron in SMA, but rather demonstrate that SMN-independent targeting of muscle enhancement may be viable as a SMA therapeutic strategy.
Collectively, our results demonstrate that follistatin improves the SMA phenotype independently of SMN levels. These results provide a rationale for examining combinatorial therapeutic strategies that directly address the genetic defect in SMA via an SMN-induction strategy as well as an SMN-independent strategy that enhances skeletal muscle.
MATERIALS AND METHODS
Animals and drug treatment
All animal experiments were carried out in accordance with protocols approved by the Animal Recombinant human follistatin (Biovision #4708) was resuspended in PBS (Invitrogen) and was administered by intraperitoneal injection at 10 µl/g of body weight, as often as indicated from p2 to p16. PBS (vehicle) was injected as a negative control. To supplement maternal feedings, the mice were hand-fed Enfamil Lipil three times per day, from p5 until death. To minimize the potential influence of litter size and SMA/wild-type ratios, pups with birth weight under 1 gram and litters containing less than 6 pups were excluded, while larger litters were reduced to 8
pups. In addition, the maximum ratio of SMA/wild-type pups allowed was 0.5. To assess strength, righting reflex (as described in (35)) was measured starting at p6.
Western blot analysis
Spinal cord (p10) or triceps (p9-10) tissues were harvested from wild-type or SMA pups (either follistatin or control treated) and immediately frozen. Tissues were resuspended in JLB buffer (50 mM Tris HCl pH 8, 150 mM NaCl, 10% glycerol, 0.1% Roche PIC, 20 mM NaH2(PO)4, 25 mM NaF, 2 mM EDTA, 1% Triton X-100) and sonicated. and re-probed with anti-IP90 polyclonal rabbit antibody at a dilution of 1:2000. Anti-T Plastin C-15 (Santa Cruz) was used at 1:200 to detect plastin levels. Probes were visualized by chemiluminescence using the Pierce SuperSignal Pico reagents.
Histology and morphometry
Lumbar regions L2-L5 of spinal columns were dissected after transcardiac perfusion, postfixed for 24 h in 4% buffered paraformaldehyde, and embedded in paraffin. Thin sections at 150 micrometer intervals were processed for Nissl staining to highlight motor neurons. Overlapping photomicrographs from each section were joined using Photoshop, and cell body area was quantified using Multigauge software (Fujifilm). Measurements were restricted to the ventral portion of the spinal column. Motor neurons were defined by the presence of a nucleolus and having a cross-sectional area greater than 250 micrometers square (46) .
Statistical analyses
Date are presented as means ± standard error unless indicated otherwise. For pairwise comparisons of parametric data, Student's t-tests were performed. Presence or absence of the righting reflex was analyzed for each day from p6 to p12 using 2x2 contingency tables and Fisher exact test to calculate P values. shown. Plastin-3 protein levels were also examined in p10 spinal cord lysates (E and F) by
Western blot, using actin as a loading control. n.s. = not significant. 
